How an mRNA-encoded antibody platform could accelerate therapies to clinic
Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process more cost-effective and faster to reach clinical use. Recent data showing preclinical feasibility suggests that this method is now a viable therapeutic option.
This webinar introduces an mRNA-LNP based platform that encodes and delivers therapeutic antibodies directly within patients. Using the anti-HER2 antibody Trastuzumab as an example, speakers demonstrate how mRNA-encoded antibodies can achieve therapeutic levels similar to those of infused recombinant antibodies.
By presenting proof-of-concept data, speakers aim to show mRNA-encoded therapeutic antibodies can be an effective alternative for solid tumor immunotherapy. This approach could democratize and improve access to biologic treatments. This session showcases in vitro and in vivo efficacy validation, the design and delivery process of mRNA-encoded antibodies, and advantages and challenges of this novel method.
Key Learning Objectives
- Discover the possibilities of mRNA-encoded antibodies compared to traditional manufacturing.
- Learn how mRNA-encoded antibodies are designed and delivered.
- Understand the safety and efficacy validation of mRNA-encoded antibodies.
- Learn how mRNA encoding might accelerate your next antibody development project.
FEATURED SPEAKERS
Roxana Redis, PhD
Associate Science Director, Advanced Modalities
Charles River Laboratories
Dan Rocca, PhD
Senior Research Leader,
Advanced Modalities
Charles River Laboratories
Sourav Mukherjee, PhD
Vice President,
Business Development
Vernal Biosciences
SCIENTIFIC POSTER
Explore how an mRNA-encoded antibody platform could accelerate therapies to clinic in this collaborative webinar and scientific poster between Charles River Labs and Vernal Biosciences.